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A pragmatic approach based on current guidelines and point-of-care platelet function testing
Antiplatelet therapy before cardiac 
surgery
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Introduction
Bleeding complications and perioperative acute coro-
nary events after coronary artery bypass grafting 
(CABG) are strongly influenced by the management of 
pre- and postoperative antithrombotic therapy. Haem-
orrhagic events needing transfusion of blood products 
increase perioperative morbidity and mortality and 
compromise the long-term benefits of CABG [1, 2].
In the last decade, antithrombotic therapy has become 
more effective and reliable, particularly in the catheter 
laboratory. Indeed, the success of percutaneous 
transluminal coronary angioplasty (PTCA) in the 
 context of an acute coronary syndrome (ACS) has 
 improved with the avail ability of new antiplatelet com-
pounds [3].
Approximately 10% of ACS non-ST-elevation myocar-
dial infarction (NSTEMI) patients will require urgent 
CABG during their acute hospitalisation, with or with-
Lecture presented at the 
 congress of the Schweizeri-
sche Gesellschaft für 
Kardiologie (SGK) 2015
Summary 
Patients under double antiplatelet therapy (DAPT) waiting for cardiac sur-
gery need careful multidisci plinary evaluation by the heart team. The de-
cisions on if and when to stop oral DAPT and if, how and for how long to 
proceed to a bridge therapy, have to be made on an individual basis taking 
into consideration the clinical urgency, coronary status, type and anatom-
ical localisation of already implanted stents and platelet function. This in-
dividualised approach is also encouraged by the newer guidelines. Point-
of-care platelet function analysis is now available and used quite widely. 
These tests can, therefore, be integrated into simple algorithms and help 
to guide decisions for perioperative management of DAPT in cardiac 
 surgery settings. The difficulties are mostly not in the function tests, but 
rather in the preanalytics and interpretation.
New compounds (e.g., cangrelor) offering rapid reversibility with intrave-
nous administration could in the future further simplify the difficult man-
agement of these patients.
Key words: cardiac surgery, antiplatelet therapy
out a stent already implanted [4]. These patients evoke 
a decisional challenge on many levels because of the 
delicate balance between effective antiplatelet treat-
ment and risk for major bleeding: choice of the right 
platelet inhibitory drug, timing of surgery, diagnostic 
and therapeutic strategy before, during and after 
CABG. There are some published data confirming the 
high bleeding rate under double antiplatelet therapy 
(DAPT) [5, 6]. There is, however, a lack of prospective, 
randomised clinical trials testing and revealing the 
best strategy in this regard. 
The clinical significance of this issue urged the various 
scientific societies and associations involved to issue 
guidelines on how to deal with DAPT and the need of 
CABG based on best available evidence and clinical 
knowledge.
The aim of this review is to summarise these guide-
lines and their recommendations according to a gener-
ally accepted methodology [7] and to suggest a tailored 
and applicable approach to these difficult clinical deci-
sions.
Overview of antiplatelet agents and 
their mechanisms of action
Several platelet inhibitory drugs with different mecha-
nisms of action and routes of administration are now-
adays available on the market. These treatments are 
routinely employed to prevent myocardial infarction 
in cases of ACS or thrombosis afte r coronary stent 
 implantation. Mechanisms of action, doses and recov-
ery times after withdrawal of the therapy to prevent 
perioperative bleeding risk during surgery are briefly 
summarised in figure 1 and table 1.
Review of current guidelines
Back in 2009 the Canadian Cardiovascular Society 
 recommended that “all ACS patients should be consid-
ered for dual antiplatelet therapy with ASA [acetyl-
salicylic acid] and clopidogrel at the earliest opportu-
nity, despite the possibility of a need for urgent CABG. 
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For patients who have received clopidogrel and ASA, 
and require CABG: those at high risk of an early fatal 
event (e.g., with refractory ischemia despite optimal 
medical treatment), and with high-risk coronary anat-
omy (e.g., severe left main stenosis with severe right 
coronary artery disease), should be considered for 
early surgery without discontinuation of clopidogrel. 
In patients with a high bleed ing risk (e.g., previous sur-
gery, complex surgery) who are also at high risk for an 
ischemic event, consideration should be given to dis-
continuing clopidogrel for three to five days before 
surgery. Patients at a lower risk for ischemic events 
Figure 1: Platelet agonists involved in platelet activation and site of action of inhibitory drugs (modified from [37], with 
 permission of Springer). ADP = adenosine diphosphate; COX = cyclo-oxygenase; GP = glycoprotein; NSAID = nonsteroidal 
 anti-inflammatory drug; PAR = protease-activated receptor
Table 1: Platelet inhibitory drugs – mechanism of action, route of administration, dose recommendations and suggested 
withdrawal before surgery. 
Drug Antiplatelet  
mechanism
Platelet  
inhibition
Administration Loading  
dose
Maintenance  
dose
Withdrawal  
before surgery
Aspirin Platelet COX-1  
inhibitor
Irreversible Oral/ 
intravenous
160–325 mg 75–100 mg  
a day
–
Clopidogrel ADP P2X12 receptor  
antagonist
Irreversible Oral 300–600 mg 75 mg a day 5 days
Prasugrel ADP P2X12 receptor  
antagonist
Irreversible Oral 60 mg 10 mg a day 7 days
Ticagrelor ADP P2X12 receptor  
antagonist
Reversible Oral 180 mg 90 mg twice  
a day
5 days
Cangrelor ADP P2X12 receptor  
antagonist
Reversible Intravenous 30 μg/kg 4 μg/kg/min  
infusion
1 hour
Abciximab Fibrinogen receptor  
(GP IIb/IIIa) antagonist
Reversible Intravenous 0.25 μg/kg 0.125 μg/kg/min 
(max. 10 μg/min)
24–48 hour
Eptifibatide Fibrinogen receptor  
(GP IIb/IIIa) antagonist
Reversible Intravenous 180 μg/kg 2 μg/kg/min 4–6 hour
Tirofiban Fibrinogen receptor  
(IIb/IIIa) antagonist
Reversible Intravenous 25 μg/kg 0.15 μg/kg/min 4–6 hour
Vorapaxar Thrombin receptor  
(PAR-1) antagonist
Reversible Oral – 2.5 mg a day ?
ADP = adenosine diphosphate; COX = cyclo-oxygenase; GP = glycoprotein; PAR = protease-activated receptor
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(most patients) should stop clopidogrel five days before 
surgery. The risk of major bleeding in patients under-
going CABG within five days of treatment with clopi-
dogrel and ASA can be minimized by applying multiple 
strategies before and dur ing surgery” [8]. Besides the 
differentiated management of antiplatelet therapy, 
which will be discussed in this paper, surgical strate-
gies aiming to minimise bleeding should also be 
 applied. Avoiding extracorporeal circulation (ECC) 
could be one of those. Should complete surgical revas-
cularisation be technically difficult in an “off pump” 
 scenario, a culprit-centered surgical approach com-
pleted by PTCA – during the same procedure or (prefer-
ably) deferred –  should be discussed and planned with 
the interventional cardiologists (hybrid revascularisa-
tion). In the case of an “on pump” procedure, coated 
ECC circuits permit the use of less heparin and can 
have a positive impact on blood activation. This can 
 reduce the amount of shed blood and activation of 
 fibrinolysis during surgery [9, 10]. The use of anti-
fibrinolytic agents such as tranexamic acid can also 
 reduce intra- and postoperative fibrinolysis and reduce 
overall bleeding [11, 12].
The Society of Thoracic Surgeons, in a 2012 guideline 
update on use of antiplatelet drugs in patients having 
cardiac and noncardiac operations, suggested that 
 aspirin could or should be discontinued before elective 
CABG in patients without ACS (Class IIa, Level B). The 
same guideline [13] stated: “Discontinuation of P2Y12 
inhibitors for a few days before cardiovascular opera-
tions is recommended to reduce bleeding and blood 
transfusion, especially in high-risk patients. Stopping 
antiplatelet drugs before operation is associated with 
reduced bleeding, blood transfusion, and reoperation 
but not with increased postoperative death, myocar-
dial infarction, or stroke. The interval between discon-
tinuation of antiplatelet drugs and operation is un-
certain and depends on multiple factors mostly related 
to patient drug responsiveness and thrombotic risk. 
This recommendation was given a Class I, Level B level 
of evidence” [13]. There was no recommendation on the 
exact number of days before surgery to discontinue 
DAPT, since “the interval between discontinuation of 
anti-platelet drugs and operation is uncertain and 
 depends on multiple factors mostly related to pa tient 
drug responsiveness and thrombotic risk” [13]. How-
ever, the same guidelines state that for patients on 
DAPT who require urgent operation “it is reasonable to 
make decisions about surgical delay based on tests of 
platelet inhibition rather than arbitrary use of a speci-
fied period of surgical delay (Class IIa, Level B)”. 
In the most recent guidelines issued by the American 
Heart Association and American College of Cardiology 
and developed in collaboration with the Society for 
Cardiovascular Angiography and Interventions and 
Society of Thoracic Surgeons [14], a specific section was 
dedicated to the timing of urgent CABG in patients 
with NSTEMI type of ACS, depending on the patient’s 
cardiac risks as well as on pharmacokinetic and phar-
macodynamic properties of antiplatelet drugs:
Non-enteric-coated aspirin (81 to 325 mg daily) should 
be administered preoperatively to patients under-
going CABG (Class I, Level B). In patients referred for 
elective CABG, clopidogrel and ticagrelor should be 
discontinued for at least 5 days before surgery (Class I, 
Level B) and prasugrel for at least 7 days before surgery 
(Class I, Level C). In patients referred for urgent CABG, 
clopidogrel and ticagrelor should be discontinued for 
at least 24 hours to reduce major bleeding (Class I, 
Level B). In patients referred for CABG, short-acting 
intra venous glyocoprotein (GP) IIb/IIIa inhibitors (epti-
fibatide or tiro fiban) should be discontinued for at least 
2 to 4 hours before surgery and abciximab for at least 
12 hours before to limit blood loss and transfusion 
(Class I, Level B). In patients referred for urgent CABG, it 
may be reason able to perform surgery less than 5 days 
after clopido grel or ticagrelor has been discontinued 
and less than 7 days after prasugrel has been discontin-
ued (Class IIb, Level C). 
The recent guidelines are completed by the “Expert 
 Position Paper” of the European Society of Cardiology 
published in 2014 [15]: there is a Class I (Level C) recom-
mendation regarding low-dose ASA: “low-dose ASA (75–
160 mg) should be maintained in patients undergoing 
CABG surgery.” However, and similar to the STS guide-
lines, for patients with increased bleeding risk and for 
those who refuse blood transfusion, withdrawal of 
ASA 3–5 days before surgery is recommended, based 
on individualised assessment of ischaemic and bleed-
ing risks [15]. Regarding the use of P2Y12 inhibitors in 
 patients needing CABG, it is recommended to postpone 
surgery for 5 days after interruption of ticagrelor or 
clopidogrel, and 7 days for prasugrel, unless the pa-
tient is at high risk of ischaemic events (Class I, Level B) 
[15]. 
The same position paper expresses important addi-
tional recommendations: 
Heart team assessment and platelet function monitor ing 
1 The risks of bleeding and thrombosis, and decision- 
making regarding DAPT and timing of surgery 
should be assessed by the heart team prior to CABG 
surgery (Class I, Level C).
2 It is reasonable to base timing of surgery on platelet 
function monitoring rather than arbitrary use of 
a specified period of delay in patients on DAPT 
(Class IIa, Level C).
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Bridging therapy
1 Bridging with cangrelor, if available, is recom-
mended in high-risk patients (Class I, Level B recom-
mendation).
2 Bridging with short-acting intravenous GPIIb/IIIa 
inhibitors may be considered in patients at high risk 
for ischaemic events (Class IIb, Level C).
Point-of-care platelet function analysis 
approach: tailoring of decision- making
Several methods for platelet function testing are avail-
able nowadays [16–19]. Most of them, as for example 
light transmission aggregometry, which is still consid-
ered the reference method and “golden standard”, 
must be performed on centrifuged platelet-rich plasma 
in a laboratory setting. These in-laboratory tests can be 
complex, time-consuming and require special labora-
tory training. Point-of-care (POC) tests on whole blood 
were recently developed. These new analyses can be 
performed outside a classical laboratory, in a near 
 pa tient setting, for example in the operating theatre or 
in the intensive care unit [20]. Potential advantages of 
this kind of test could be readily available results, sim-
plified workflow (rapid turnaround time, no transport 
of sample to laboratory) and targeted management of 
coagulation disorders. Of this newly available technol-
ogy, two devices (VerifyNow® and Multiplate®) are the 
more routinely employed to assess efficacy and inten-
sity of DAPT in cardiac patients. 
VerifyNow® (Accumetrics, San Diego, CA, USA) is a fully 
automated device not requiring any pipetting. A cirat-
 ed tube containing the blood sample is directly in-
serted within the mixing chamber of special dispos-
able cartridges. Cartridges contain fibrinogen-coated 
polystyrene beads and specific platelet activators [ara-
chidonic acid (AA) or adenosine diphosphate (ADP)]. 
Stimulated platelets activate GPIIb/IIIa receptors on 
their surface, which bind fibrinogen on the beads. 
 Agglutinated beads and platelets complexes fall out of 
the solution, which becomes more transparent. Light 
transmittance through the mixing chamber is contin-
uously measured by the device and directly correlated 
Figure 2: Working mechanism of VerifyNow® system (modified from [37], with permission of Springer).
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to the proportion of platelet activation. Direct pharma-
cological blockade of receptors or decrease of their 
 expression by inhibitor drugs diminishes platelet ag-
gregation and therefore light transmittance (fig. 2).
The Multiplate® analyser (Roche Diagnostics,  Rotkreuz, 
Switzerland) is a whole-blood assay that utilises elec-
trical impedance aggregometry to measure platelet 
function [21]. Impedance aggregometry is based on the 
principle that platelets are nonthrombogenic in their 
resting state, but change shape and expose receptors 
on their surface when activated, allowing them to 
 adhere to vascular injuries and artificial surfaces. The 
Multiplate® analyser provides a disposable test cuvette 
containing two independent sensor units, each con-
sisting of two highly conductive metallic wires. A small 
quantity of whole blood anticoagulated with hirudin is 
mixed with a saline solution and incubated briefly. A 
specific platelet activator is then added to the solution 
(e.g., AA, ADP or thrombin-receptor- activating peptide 
[TRAP]). Activated platelets adhere to and aggregate on 
sensor electrodes immersed in blood. This leads to an 
enhanced resistance between sensor metallic wires, 
which is continuously recorded (over a 6-minute 
 period) and expressed as aggregation units (fig. 3).
In conclusion, light transmittance aggregometry (Veri-
fyNow®) and impedance aggregometry (Multiplate®) 
are two bedside platelet function analysis devices able 
to measure, in whole blood, specific drug-induced 
platelet inhibition. Resistance (high on-treatment 
platelet reactivity) to some antithrombotic therapies 
(e.g., clopidogrel) or strong inhibition associated with 
increased risk of bleeding can nowadays be quickly 
and easily measured in the perioperative setting. It has 
to be noted, however, that platelet aggregation by itself 
might be inadequate to assess the bioavailability of an 
antiplatelet agent [22] and its potential effects on clini-
cally relevant thrombotic or bleeding events.
Discussion 
Drug-eluting stents were introduced more than 10 
years ago with a main aim to counteract the significant 
rate of restenosis occurring with bare metal stents. The 
antiproliferative properties of the eluted drugs were 
Figure 3: Working mechanism of impedance aggregometry Multiplate® (modified from [37], with permission of Springer).
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proved to be effective against the proliferation of 
smooth muscle cells. At the same time, however, they 
inhibited and delayed new endothelialisation, result-
ing in longer exposure of thrombogenic material to 
the bloodstream [23]. The need to increase the inten-
sity and specificity, as well as to prolong the duration, 
of DAPT was the direct consequence and the right 
choice to protect patients from deleterious acute stent 
thrombosis [24]. There are still more aspects of mid-
term DAPT to be clarified for every specific stent sub-
category, but the tendency seems, however, to be to-
wards longer periods of DAPT therapy. 
In the acute setting, especially NSTEMI-type of ACS, 
and with special regard to patients needing urgent (or 
emergent) CABG surgery, the right strategy is more 
 difficult to standardise. Clinical instability can impose 
an earlier than foreseen operation, which in turn can 
cause significant bleeding despite best efforts to treat 
coagulopathy during and after surgery. Here the indi-
vidualised concept of the POC measurements can 
eventually help us with the decision. 
In cardiac surgery, especially on pump, bleeding can 
be associated with multifactorial causes. Preoperative 
strong antiplatelet-drug-induced inhibition is an im-
portant contributory factor that is correlated with 
 increased postoperative bleeding and platelet transfu-
sion requirement [2, 25–30]. 
Preoperative platelet function analysis can, therefore, 
be helpful to assess bleeding risk before cardiac sur-
gery in patients treated with DAPT. A clear cut-off value 
of platelet function that avoids severe perioperative 
bleeding has not been identified so far.
Two single-centre retrospective studies using imped-
ance aggregometry (Multiplate®) showed a relation-
ship between intensity of preoperative thienopyridine 
inhibition of the P2Y12 receptor and severity of periop-
erative bleeding [26, 31]. In the first study, published in 
2011, the primary endpoint was severe postoperative 
bleeding defined as more than 800 ml chest drain 
blood loss in the in first 12 postoperative hours. A cut-
off value for the ADP test at 31 U predicted postopera-
tive severe bleeding quite accurately. In a second retro-
spective study, published by the same group in 2014 
and including a larger cohort of 361 patients, severe 
bleeding was defined in a more restrictive way using 
the Universal Definition of Perioperative Bleeding in 
Figure 4: Preoperative decisional flow-chart as used currently at the Cardiocentro Ticino. 
ADP = adenosine diphosphate; TRAP = thrombin receptor activating peptide
Dual antiplatelet therapy 
Indication for cardiac 
surgery 
Yes 
No 
Perform surgery 
with usual 
precautions 
High hemorrhagic risk 
Alert blood bank for thrombocyte 
transfusions 
Desmopressin  0.3mcg/kg iv 
 
ADP < 31U 
& 
TRAP <75U 
 
Wait and 
perform surgery 
only when ADP 
≥31 U 
& TRAP  ≥75 U 
Yes 
No Intracoronary 
stent with high 
thrombosis 
risk 
Consider perioperative 
anti-GP IIb/IIIa bridging 
therapy 
Yes 
No 
Perform 
scheduled 
surgery 
Stop P2Y12 
inhibition - 
continue 
with aspirin 
Tranexamic acid 15 - 30mg/kg 
is administered intra-operatively 
to all patients 
Preoperative algorithm for patients on dual antiplatelet therapy with indication for cardiac sugery 
 
ADP < 31U 
& 
TRAP <75U 
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adult cardiac surgery (severe bleeding defined as drain 
fluid loss >1000 ml in the first 12 postoperative hours, 
or need of surgical re-exploration, or need of >5 units 
of red blood cells or fresh frozen plasma). In this study 
the ADP threshold was lower than in the first publica-
tion. A threshold of 22 U yielded a negative predictive 
value for severe postoperative bleeding of 94%. Throm-
bin platelet activation capacity (via protease-activated 
receptor stimulation) was also assessed using the 
thrombin receptor activating peptide (TRAP) test. A 
TRAP test result of ≥75 U was associated with a negative 
predictive value of 95% for severe postoperative bleed-
ing [31].
POC coagulation assessment was introduced 5 years 
ago by anaesthesiologists in our centre and since then 
has been routinely used to check perioperative haemo-
stasis. Impedance aggregometry on whole blood (Multi-
plate®) was locally chosen by us as platelet function 
analyzer on the basis of highly correlated results and 
good agreement with the in-laboratory reference 
method (light transmission aggregometry on centri-
fuged platelet-rich plasma [32, 33] despite some conflict-
ing cross-comparisons [34, 35]). Furthermore, Multi-
plate® showed satisfactory validity in the perioperative 
cardiosurgical setting [36]. Notwithstanding little 
widely confirmed scientific evidence, we locally de-
cided to develop a simple individualised decision-mak-
ing preoperative algorithm based on platelet function 
for cardiosurgical patients on DAPT. This algorithm is 
intended to help us to determine the time of surgery 
and management of perioperative antiplatelet therapy. 
Platelet function is assessed in our centre by imped-
ance aggregometry on whole blood (Multiplate®). Our 
local algorithm (fig. 4) is based on the few published 
studies presented above. It has to be stressed that this 
approach is not further validated and needs to be con-
firmed by appropriate trials or at least registries report-
ing on bleeding rates, particularly if the operation took 
place earlier than recommended, based on the POC 
 result. In order to limit as much as possible the risk of 
bleeding of our surgical patients, we decided to keep in 
our algorithm the most protective ADP test cut-off of 
31 U [26], even after publication of the second study of 
Ranucci et al. [31]. Simultaneous TRAP testing is also 
 always assessed and a recovery of more than 75 U is 
mandatory to confirm an adequate response to throm-
bin-mediated activation of the platelets and to further 
decrease the risk of severe bleeding.
POC coagulation assessment can be a useful adjunct in 
our decisional armamentarium when we are called on 
to operate on patients under DAPT. Carefully designed 
and monitored randomised studies are needed to 
 verify the validi ty of this approach.
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